UBS analyst AJ Rice lowered the firm’s price target on UnitedHealth (UNH) to $385 from $400 and keeps a Buy rating on the shares. UBS expects a “prudent” reinstatement of guidance and views the Q2 earnings release in late July as a clearing event, the analyst tells investors in a research note.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UNH:
- UnitedHealth recommends shareholders reject mini-tender offer by Tutanota
- HHS, CMS announce pledge from insurers to improve MA authorization process
- Lawmakers aim at VA loophole letting insurers charge Medicare billions, WSJ says
- ‘Jump the Gun,’ Says Investor About UnitedHealth Stock
- UnitedHealth Sells $3 Billion in Notes